📊 ELDN Key Takeaways
Is Eledon Pharmaceuticals, Inc. (ELDN) a Good Investment?
Eledon is a pre-revenue clinical-stage pharmaceutical company with $39M annual net losses and $22.6M quarterly operating cash burn against only $6.2M cash reserves, providing less than 3 months of operational runway. Despite a strong balance sheet structure ($146.7M assets, zero debt), the company exhibits deteriorating profitability (-32.3% YoY loss increase) and zero revenue generation, indicating significant execution risk without near-term approved products or financing catalysts evident in the data.
Eledon Pharmaceuticals remains a pre-revenue development-stage biotech with no operating income and substantial recurring losses, so current fundamentals do not yet support a strong positive view. The balance sheet is a relative strength because liquidity is high and leverage is minimal, but negative operating cash flow and free cash flow indicate ongoing dependence on cash reserves or future capital raises. Until the company shows meaningful clinical and commercial progress translating into revenue, fundamentals remain weak.
Eledon Pharmaceuticals, Inc. Key Strengths (ELDN)
- No debt burden with clean capital structure
- Strong current ratio of 8.44x indicating sufficient liquid assets for short-term obligations
- Substantial asset base of $146.7M providing development capital
- Strong liquidity profile with 7.40x current and quick ratios
- Debt-free balance sheet reduces financial risk
- Net loss per share improved year over year, indicating some dilution or cost-control benefit
ELDN Stock Risks: Eledon Pharmaceuticals, Inc. Investment Risks
- Zero revenue with no indication of approved or near-market products
- Unsustainable cash burn rate of $22.6M quarterly against only $6.2M cash reserves
- Net losses worsening year-over-year by 32.3% indicating accelerating cash consumption
- Critical liquidity crisis likely within 3 months without additional financing or revenue generation
- High execution risk typical of pre-clinical/early-stage pharmaceutical development
- No revenue base, making profitability and margin analysis impossible
- Heavy cash burn with operating cash flow of -$62.34M and free cash flow of -$62.36M
- Negative returns on equity and assets show inefficient capital use and continued operating weakness
Key Metrics to Watch
- Cash position and monthly burn rate (critical for survival timeline)
- Clinical trial results and FDA approval status for pipeline candidates
- Operating cash flow and whether losses stabilize or accelerate
- Financing activities and dilutive capital raises
- Quarterly operating cash burn relative to cash and equivalents
- Any emergence of collaboration revenue, milestone payments, or commercialization progress
Eledon Pharmaceuticals, Inc. (ELDN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.44x current ratio provides a solid financial cushion.
ELDN Profit Margin, ROE & Profitability Analysis
ELDN vs Healthcare Sector: How Eledon Pharmaceuticals, Inc. Compares
How Eledon Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Eledon Pharmaceuticals, Inc. Stock Overvalued? ELDN Valuation Analysis 2026
Based on fundamental analysis, Eledon Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Eledon Pharmaceuticals, Inc. Balance Sheet: ELDN Debt, Cash & Liquidity
ELDN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Eledon Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.66 indicates the company is currently unprofitable.
ELDN Revenue Growth, EPS Growth & YoY Performance
ELDN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2017 | N/A | -$3.9M | N/A |
| Q3 2016 | N/A | -$9.3M | N/A |
| Q2 2016 | N/A | -$9.0M | N/A |
| Q1 2016 | N/A | -$11.4M | N/A |
| Q3 2015 | N/A | -$6.4M | N/A |
| Q2 2015 | N/A | -$5.9M | N/A |
| Q1 2015 | N/A | -$4.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Eledon Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
ELDN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Eledon Pharmaceuticals, Inc. (CIK: 0001404281)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELDN
What is the AI rating for ELDN?
Eledon Pharmaceuticals, Inc. (ELDN) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELDN's key strengths?
Claude: No debt burden with clean capital structure. Strong current ratio of 8.44x indicating sufficient liquid assets for short-term obligations. ChatGPT: Strong liquidity profile with 7.40x current and quick ratios. Debt-free balance sheet reduces financial risk.
What are the risks of investing in ELDN?
Claude: Zero revenue with no indication of approved or near-market products. Unsustainable cash burn rate of $22.6M quarterly against only $6.2M cash reserves. ChatGPT: No revenue base, making profitability and margin analysis impossible. Heavy cash burn with operating cash flow of -$62.34M and free cash flow of -$62.36M.
What is ELDN's revenue and growth?
Eledon Pharmaceuticals, Inc. reported revenue of $0.0.
Does ELDN pay dividends?
Eledon Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find ELDN SEC filings?
Official SEC filings for Eledon Pharmaceuticals, Inc. (CIK: 0001404281) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELDN's EPS?
Eledon Pharmaceuticals, Inc. has a diluted EPS of $-0.33.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ELDN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Eledon Pharmaceuticals, Inc. has a C grade with 84% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ELDN stock overvalued or undervalued?
Valuation metrics for ELDN: ROE of -87.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ELDN's AI grade for 2026?
Our dual AI analysis gives Eledon Pharmaceuticals, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELDN's free cash flow?
Eledon Pharmaceuticals, Inc.'s operating cash flow is $-22.6M, with capital expenditures of $17.0K.
How does ELDN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -87.2% (avg: 15%), current ratio 8.44 (avg: 2).